ArticlePsychopharmacology2022
Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey.
Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026Article
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Pharmacological topics of interest for young people: misinformation on TikTok is common.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Phytocannabinoid-drug interactions: pharmacokinetic and pharmacodynamic mechanisms, clinical relevance and toxicological considerations.Frontiers in toxicology · 2026Review
- Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times.Journal of psychopharmacology (Oxford, England) · 2025Article
- Exploring Gender-Themed Lysergic Acid Diethylamide Experiences: A Subreddit Analysis.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- A qualitative analysis of the psychedelic mushroom come-up and come-down.Npj mental health research · 2025Article
- Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.Child and adolescent psychiatry and mental health · 2024Review
- Effects of Psychedelics in Older Adults: A Prospective Cohort Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2024Observational
- Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado: characterizing enhancement and adverse reactions using mixed methods.Journal of cannabis research · 2024Article
- Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.Journal of psychopharmacology (Oxford, England) · 2024Article
- Case analysis of long-term negative psychological responses to psychedelics.Scientific reports · 2023Article
- Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.Scientific reports · 2023Article
- Pattern breaking: a complex systems approach to psychedelic medicine.Neuroscience of consciousness · 2023Article
- Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey.British journal of pain · 2022Article
- Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.Journal of psychopharmacology (Oxford, England) · 2022Article
- Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.Harm reduction journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleClassic psychedelics are currently being studied as novel treatments for a range of psychiatric disorders. However, research on how psychedelics interact with other psychoactive substances remains scarce.
objectivesThe current study aimed to explore the subjective effects of psychedelics when used alongside cannabis.
methodsParticipants (n = 321) completed a set of online surveys at 2 time points: 7 days before, and 1 day after a planned experience with a serotonergic psychedelic. The collected data included demographics, environmental factors (so-called setting) and five validated questionnaires: Mystical Experience Questionnaire (MEQ), visual subscales of Altered States of Consciousness Questionnaire (ASC-Vis), Challenging Experience Questionnaire (CEQ), Ego Dissolution Inventory (EDI) and Emotional Breakthrough Inventory (EBI). Participants were grouped according to whether they had reported using no cannabis (n = 195) or low (n = 53), medium (n = 45) or high (n = 28) dose, directly concomitant with the psychedelic. Multivariate analysis of covariance (MANCOVA) and contrasts was used to analyse differences in subjective effects between groups while controlling for potential confounding contextual 'setting' variables.
resultsThe simultaneous use of cannabis together with classic serotonergic psychedelics was associated with more intense psychedelic experience across a range of measures: a linear relationship was found between dose and MEQ, ASC-Vis and EDI scores, while a quadratic relationship was found for CEQ scores. No relationship was found between the dose of cannabis and the EBI.
conclusionsResults imply a possible interaction between the cannabis and psychedelic on acute subjective experiences; however, design limitations hamper our ability to draw firm inferences on directions of causality and the clinical implications of any such interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.